DBVT
DBV TechnologiesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$978.95M
P/E Ratio
—
EPS
$-4.50
Beta
-0.22
52W High
$26.18
52W Low
$8.50
50-Day MA
$19.48
200-Day MA
$17.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Fundamentals
| Revenue (TTM) | $5.74M |
| Gross Profit (TTM) | $5.74M |
| EBITDA | $-165.16M |
| Operating Margin | -5311.00% |
| Return on Equity | -158.90% |
| Return on Assets | -66.40% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $3.52 |
| Price-to-Book | 4.70 |
| Price-to-Sales (TTM) | 170.67 |
| EV/Revenue | 24.3 |
| EV/EBITDA | -2.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $59.19M |
| Float | $35.25M |
| % Insiders | 0.00% |
| % Institutions | 37.23% |
Historical Volatility
HV 10-Day
51.67%
HV 20-Day
42.34%
HV 30-Day
41.36%
HV 60-Day
47.51%
HV Rank
7.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($40.45 target)
1
Strong Buy4
Buy1
SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026